|
Sun, 03/09/2025 - 08:57 |
ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025 |
GlaxoSmithKline |
|
Fri, 10/21/2022 - 09:17 |
Howard University Pharmacy Researcher Receives $1.3 Million in NIH Grants to Study HIV Cure and Triple-Negative Breast Cancer |
Howard University |
|
Mon, 09/19/2022 - 21:05 |
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection |
Merck |
|
Wed, 11/24/2021 - 13:54 |
HIV drug resistance report 2021 |
WHO |
|
Wed, 06/30/2021 - 19:18 |
Lupin Receives Tentative U.S. FDA Approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR |
Lupin |
|
Fri, 06/25/2021 - 08:11 |
Mumbai, Baltimore, June 25, 2021: Global pharma major Lupin Limited (Lupin) today announced the launch of Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg, having received an approval from the United States Food and Drug Administratio |
Lupin |
|
Thu, 01/21/2021 - 18:43 |
FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV |
FDA |
|
Fri, 11/20/2020 - 02:11 |
HIV drug resistance: World Antimicrobial Awareness Week 2020 |
WHO |
|
Fri, 10/30/2020 - 10:49 |
New Cause of Inflammation in People with HIV Identified |
Boston Medical ... |
|
Wed, 10/07/2020 - 14:49 |
Hologic Panther Platform and HIV-1 Quant Assay Used in HIV Cure Research |
Hologic |
|
Fri, 09/18/2020 - 06:56 |
Successful continuation of antiretroviral therapy delivery during COVID 19 best practices from the South East Asia Region |
WHO |
|
Tue, 08/04/2020 - 20:12 |
UNM's Gold Lab works toward improved HIV treatment |
University of N... |
|
Tue, 07/07/2020 - 03:54 |
Injectable PrEP is Highly Effective for Some Populations and Must Move Forward as Quickly as Possible |
AIDS Vaccine Ad... |
|
Thu, 07/02/2020 - 15:32 |
FDA Approves New HIV Treatment for Patients With Limited Treatment Options |
FDA |
|
Wed, 06/24/2020 - 05:31 |
World AIDS Day 2020 WHO calls for global solidarity to maintain HIV services |
WHO |
|
Tue, 06/16/2020 - 16:06 |
Gladstone Investigator Receives an Avant-Garde Award |
Gladstone Institutes |
|
Fri, 06/12/2020 - 09:47 |
FDA Approves Drug to Treat Infants and Children with HIV |
FDA |
|
Thu, 06/11/2020 - 06:21 |
Brain cells can harbor and spread HIV virus to the body |
NIH |
|
Wed, 05/13/2020 - 16:35 |
Yale researchers discover how HIV hides from treatment |
YaleUniversity |
|
Wed, 04/22/2020 - 07:41 |
Egypt: Covid-19 Threatens Treatment for HIV Patients |
Human Rights Watch |
|
Thu, 03/19/2020 - 23:37 |
Janssen Announces Health Canada Approval of CABENUVA, the First Long-Acting Regimen for the Treatment of HIV |
Johnson and Johnson |
|
Thu, 03/19/2020 - 22:53 |
ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV |
ViiV Healthcare |
|
Tue, 03/10/2020 - 21:31 |
New Clinical Study Data for Gileads Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020 |
Gilead Sciences |
|
Tue, 03/10/2020 - 21:21 |
Newer anti-HIV drugs safest, most effective during pregnancy |
NIH |
|
Mon, 03/09/2020 - 10:47 |
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing |
GlaxoSmithKline |
